Mps1/TTK kinase inhibitor to treat hematological malignancies
The TTK kinase is critical for proper function of the spindle assembly checkpoint, and its upregulation is associated with poor clinical outcomes in a variety of cancer types. TTK kinase inhibition in cancer cells, especially those featuring significant chromosomal instability, leads to aneuploid phenotypes incompatible with cell viability.
The Ohio State University’s Drug Development Institute (DDI) is developing an orally bioavailable, brain penetrant small molecule inhibitor of TTK. Highlighting efficacy of our lead compound in multiple in vivo tumor models, as well as ongoing lead characterization and optimization, the DDI will report on progress toward selection of a preclinical candidate.